abstract |
Disclosed is the use of 4-iodo-3-nitrobenzamide (pictured), or a metabolite or a pharmaceutically acceptable salt thereof, and at least one topoisomerase inhibitor for the treatment of metastatic ovarian cancer. Suitable topoisomerase inhibitors include topotecan, irinotecan, lurtotecan, exatecan and camptothecin. |